Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results : (231) Arrow Down
Filter Results : (231) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (485)
    • Faculty Publications  (231)

    Show Results For

    • All HBS Web  (485)
      • Faculty Publications  (231)

      Biotechnology Industry Remove Biotechnology Industry →

      Page 1 of 231 Results →

      Are you looking for?

      → Search All HBS Web
      • January 2023
      • Case

      Vertex and the Cure for Type 1 Diabetes

      By: Amitabh Chandra, William J Anderson and Silvia Mare
      Keywords: Biotechnology Industry
      Citation
      Educators
      Related
      Chandra, Amitabh, William J Anderson, and Silvia Mare. "Vertex and the Cure for Type 1 Diabetes ." Harvard Business School Case 623-053, January 2023.
      • October 2022 (Revised October 2022)
      • Case

      Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues

      By: Aiyesha Dey, Jonas Heese, Suraj Srinivasan and Annelena Lobb
      Ginkgo Bioworks, a synthetic biology company based in Boston, Massachusetts, faced divergent views on its revenue possibilities and accounting practices. After a report emerged accusing it of fraudulent accounting and lack of innovation, its share price plunged. But...  View Details
      Keywords: Fraud Allegations; Revenue; Reports; Accounting Audits; Innovation and Management; Investment; Biotechnology Industry; Boston
      Citation
      Educators
      Related
      Dey, Aiyesha, Jonas Heese, Suraj Srinivasan, and Annelena Lobb. "Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues." Harvard Business School Case 123-037, October 2022. (Revised October 2022.)
      • March 2022
      • Teaching Note

      Digital Manufacturing at Amgen

      By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
      This teaching note provides guidance for instructors teaching “Digital Manufacturing at Amgen,” case no. 621-008.  View Details
      Keywords: Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information Technology; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Technology Adoption; Biotechnology Industry; Biotechnology Industry; United States; California; Puerto Rico; Rhode Island
      Citation
      Purchase
      Related
      Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Teaching Note 622-013, March 2022.
      • Article

      Internal Deadlines, Drug Approvals, and Safety Problems

      By: Lauren Cohen, Umit Gurun and Danielle Li
      Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly...  View Details
      Keywords: Health; Economics; Government and Politics; Innovation and Invention; Research; Science; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
      Citation
      SSRN
      Find at Harvard
      Related
      Cohen, Lauren, Umit Gurun, and Danielle Li. "Internal Deadlines, Drug Approvals, and Safety Problems." American Economic Review: Insights 3, no. 1 (March 2021): 67–82.
      • February 2021
      • Case

      Digital Manufacturing at Amgen

      By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
      This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is...  View Details
      Keywords: Digital Technologies; Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Information Technology; Technology Adoption; Biotechnology Industry; Biotechnology Industry; United States; California; Puerto Rico; Rhode Island
      Citation
      Educators
      Purchase
      Related
      Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Case 621-008, February 2021.
      • January 2021
      • Case

      Takeda Pharmaceutical Company Limited (A)

      By: David J. Collis, Nobuo Sato and Akiko Kanno
      This case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition would turn...  View Details
      Keywords: Pharmaceutical Companies; Pharmaceuticals; Biotech; Biotechnology; M&A; Mergers & Acquisitions; R&D; Talent Management; Mergers and Acquisitions; Globalization; Management; Global Strategy; Talent and Talent Management; Pharmaceutical Industry; Pharmaceutical Industry; Japan; Asia
      Citation
      Educators
      Purchase
      Related
      Collis, David J., Nobuo Sato, and Akiko Kanno. "Takeda Pharmaceutical Company Limited (A)." Harvard Business School Case 721-373, January 2021.
      • January 2021
      • Supplement

      Takeda Pharmaceutical Company Limited (B)

      By: David J. Collis, Nobuo Sato and Akiko Kanno
      This case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challenges Takeda and...  View Details
      Keywords: Pharmaceutical Companies; Pharmaceuticals; M&A; Mergers & Acquisitions; Biotech; Biotechnology; R&D; Talent Management; Mergers and Acquisitions; Globalization; Global Strategy; Talent and Talent Management; Strategy; Biotechnology Industry; Biotechnology Industry; Japan; Asia
      Citation
      Purchase
      Related
      Collis, David J., Nobuo Sato, and Akiko Kanno. "Takeda Pharmaceutical Company Limited (B)." Harvard Business School Supplement 721-374, January 2021.
      • January 2021 (Revised December 2021)
      • Case

      Biobot Analytics

      By: Raymond Kluender, Joshua Krieger and Mitchell Weiss
      In 2017, Newsha Ghaeli and Mariana Matus were deciding whether to leave their labs at the Massachusetts Institute of Technology, put other job opportunities aside, and dive full-time into founding a wastewater analysis start-up, Biobot. Ghaeli, an architect, and Matus,...  View Details
      Keywords: Entrepreneurship; Information Technology; City; Analytics and Data Science; Personal Development and Career; Technology Industry; Technology Industry; Technology Industry; Technology Industry; Technology Industry; Technology Industry; United States; Kuwait; Korean Peninsula
      Citation
      Educators
      Purchase
      Related
      Kluender, Raymond, Joshua Krieger, and Mitchell Weiss. "Biobot Analytics." Harvard Business School Case 821-045, January 2021. (Revised December 2021.)
      • November 2020
      • Teaching Note

      Valuing Celgene's CVR

      By: Benjamin C. Esty and Daniel Fisher
      When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage...  View Details
      Keywords: Mergers and Acquisitions; Valuation; Value; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Pharmaceutical Industry; United States
      Citation
      Related
      Esty, Benjamin C., and Daniel Fisher. "Valuing Celgene's CVR." Harvard Business School Teaching Note 221-036, November 2020.
      • November 2020
      • Supplement

      Valuing Celgene's CVR

      By: Benjamin C. Esty and Daniel Fisher
      When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage...  View Details
      Keywords: Mergers and Acquisitions; Value; Valuation; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Pharmaceutical Industry; United States
      Citation
      Purchase
      Related
      Esty, Benjamin C., and Daniel Fisher. "Valuing Celgene's CVR." Harvard Business School Spreadsheet Supplement 221-705, November 2020.
      • November 2020
      • Case

      Valuing Celgene's CVR

      By: Benjamin C. Esty and Daniel Fisher
      When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage...  View Details
      Keywords: Mergers and Acquisitions; Value; Valuation; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Pharmaceutical Industry; United States
      Citation
      Educators
      Related
      Esty, Benjamin C., and Daniel Fisher. "Valuing Celgene's CVR." Harvard Business School Case 221-031, November 2020.
      • October 2020 (Revised April 2022)
      • Case

      When Institutions Fail: HIV/AIDS in the 1980s

      By: Tom Nicholas and Christian Godwin
      During the early 1980s, young gay men in urban centers such as San Francisco and New York City began contracting a mysterious illness that would come to be known as HIV/AIDS. A diagnosis meant almost certain death, with a less than 1% survival rate. Conflicting...  View Details
      Keywords: Ethics; Policy; Government and Politics; Health Pandemics; History; Rights; Media; Organizations; Business and Community Relations; Religion; Social Psychology; Identity; Prejudice and Bias; Social Issues; Public Opinion; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
      Citation
      Educators
      Purchase
      Related
      Nicholas, Tom, and Christian Godwin. "When Institutions Fail: HIV/AIDS in the 1980s." Harvard Business School Case 821-002, October 2020. (Revised April 2022.)
      • September 2020 (Revised January 2021)
      • Case

      Catalys Pacific

      By: Joshua Lev Krieger
      In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After...  View Details
      Keywords: Pharmaceutical Companies; Biotech; Health Care; Entrepreneur; Innovation; International Business; Entrepreneurial Finance; Entrepreneurship; Finance; Innovation Strategy; Venture Capital; Strategy; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; Pharmaceutical Industry; Tokyo
      Citation
      Educators
      Purchase
      Related
      Krieger, Joshua Lev. "Catalys Pacific." Harvard Business School Case 821-035, September 2020. (Revised January 2021.)
      • 2020
      • Book

      Work, Mate, Marry, Love: How Machines Shape Our Human Destiny

      By: Debora L. Spar
      Covering a time frame that ranges from 8000 BC to the present, and drawing upon both Marxist and feminist theories, the book argues that nearly all the decisions we make in our most intimate lives—whom to marry, how to have children, how to have sex, how to think about...  View Details
      Keywords: Innovation; Family; Women; Reproduction; Artificial Intelligence; Robots; Gender; Demography; History; Innovation and Invention; Relationships; Society; Information Technology; AI and Machine Learning; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Africa; Asia; Europe; Latin America; North and Central America
      Citation
      Purchase
      Related
      Spar, Debora L. Work, Mate, Marry, Love: How Machines Shape Our Human Destiny. New York: Farrar, Straus and Giroux, 2020.
      • June 2020
      • Case

      Breakthroughs at Blueprint Medicines

      By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
      Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development...  View Details
      Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
      Citation
      Educators
      Purchase
      Related
      Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
      • June 2020 (Revised March 2020)
      • Case

      Social Salary Setting at Spiber

      By: Ashley Whillans and John Beshears
      Can a “set your own salary” system boost employee happiness and motivation? Spiber made synthetic silk built from proteins mimicking the proteins found in spider silk, the world’s toughest known material by weight. Kazuhide Sekiyama and Junichi Sugahara established...  View Details
      Keywords: Compensation and Benefits; Motivation and Incentives; Happiness; Negotiation Tactics; Cross-Cultural and Cross-Border Issues; Biotechnology Industry; Japan; United States
      Citation
      Educators
      Purchase
      Related
      Whillans, Ashley, and John Beshears. "Social Salary Setting at Spiber." Harvard Business School Case 920-050, June 2020. (Revised March 2020.)
      • November 2019 (Revised April 2020)
      • Technical Note

      The Life Sciences Revolution: A Technical Primer

      By: Gary P. Pisano, William J. Anderson, Amitabh Chandra, Clarissa Ceruti and Stephanie Oestreich
      For more than two decades, scientific advances have been driving profound changes in drug discovery and the drug industry itself. This case provides an overview and description of these technical and scientific advances. Written for the nonscientific reader, it may be...  View Details
      Keywords: Science; Technological Innovation; Technology; Pharmaceutical Industry; Pharmaceutical Industry
      Citation
      Educators
      Purchase
      Related
      Pisano, Gary P., William J. Anderson, Amitabh Chandra, Clarissa Ceruti, and Stephanie Oestreich. "The Life Sciences Revolution: A Technical Primer." Harvard Business School Technical Note 620-054, November 2019. (Revised April 2020.)
      • October 2019 (Revised April 2020)
      • Background Note

      Note on Funding Deep Tech Startups

      By: Karim Lakhani, Peter Barrett and Noubar Afeyan
      This Background Note provides essential information on funding deep technologies—those technologies that were inherently capital intensive, time consuming, risky, and potentially disruptive. Both dilutive and non-dilutive sources of investment are highlighted, along...  View Details
      Keywords: Entrepreneurship; Energy; Venture Capital; Corporate Finance; Initial Public Offering; Investment; Health Testing and Trials; Innovation and Invention; Technological Innovation; Intellectual Property; Product Design; Product Development; Information Technology; Research and Development; Risk and Uncertainty; Technology Industry; Technology Industry; United States; North America; Europe; Asia
      Citation
      Educators
      Purchase
      Related
      Lakhani, Karim, Peter Barrett, and Noubar Afeyan. "Note on Funding Deep Tech Startups." Harvard Business School Background Note 620-029, October 2019. (Revised April 2020.)
      • September 2019 (Revised August 2020)
      • Case

      Engineering an Inclusive Bioeconomy

      By: Tarun Khanna, Raffaella Sadun and Susie L. Ma
      In 2019, entrepreneur Juan Carlos Castilla-Rubio was developing a project he hoped could generate and share wealth from the natural resources of the Amazon without destroying those resources. His idea, called Earth Bank of Codes (EBC), would create a library of the...  View Details
      Keywords: Decision Making; Development Economics; Entrepreneurship; Innovation and Invention; Intellectual Property; Emerging Markets; Market Design; Marketplace Matching; Science; Genetics; Natural Environment; Environmental Sustainability; Climate Change; Social Enterprise; Strategy; Strategic Planning; Information Technology; Ownership; Social Psychology; Trust; Society; Biotechnology Industry; South America; Amazon Basin
      Citation
      Educators
      Purchase
      Related
      Khanna, Tarun, Raffaella Sadun, and Susie L. Ma. "Engineering an Inclusive Bioeconomy." Harvard Business School Case 720-356, September 2019. (Revised August 2020.)
      • September 2019
      • Case

      Nimbus Therapeutics

      By: Peter Barrett, Karim Lakhani and Julia Kelley
      This case focuses on Nimbus Therapeutics, a biotechnology startup based in Cambridge, Massachusetts, as its leadership team tries to determine the company’s long-term strategy. The startup’s founders structured Nimbus as a limited liability company, which has given it...  View Details
      Keywords: Business Startups; Organizational Structure; Strategy; Biotechnology Industry
      Citation
      Educators
      Purchase
      Related
      Barrett, Peter, Karim Lakhani, and Julia Kelley. "Nimbus Therapeutics." Harvard Business School Case 620-016, September 2019.
      • 1
      • 2
      • …
      • 11
      • 12
      • →

      Are you looking for?

      → Search All HBS Web
      ǁ
      Campus Map
      Harvard Business School
      Soldiers Field
      Boston, MA 02163
      →Map & Directions
      →More Contact Information
      • Make a Gift
      • Site Map
      • Jobs
      • Harvard University
      • Trademarks
      • Policies
      • Accessibility
      • Digital Accessibility
      Copyright © President & Fellows of Harvard College